Data as of Jul 25, 2026 · Based on 2,718,867 AI responses across 9,511 prompts · See how Parse measures this
GOMEKLIgomekli.com · Low evidenceGOMEKLI (mirdametinib) is the first FDA-approved treatment for adults and children aged 2 and older with symptomatic neurofibromatosis type 1 (NF1) and plexiform neurofibromas (PN) that cannot be completely removed by surgery. It is available in capsules or tablets for oral suspension, and the company offers financial support and a digital companion app to help patients manage their treatment.
Parse Score